Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life by Abhishek Saxena & Donghui Wu
December 2016 | Volume 7 | Article 5801
Review
published: 12 December 2016
doi: 10.3389/fimmu.2016.00580
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Tianlei Ying, 
Fudan University, China
Reviewed by: 
Pierre Guermonprez, 
King’s College London, UK  
Estrella Mariel Levy, 
National Scientific and Technical 
Research Council, Argentina  
Shane Miersch, 
University of Toronto, Canada
*Correspondence:
Donghui Wu  
wudh@shanghaitech.edu.cn
Specialty section: 
This article was submitted to 
Immunotherapies and Vaccines, 
a section of the journal 
Frontiers in Immunology
Received: 12 July 2016
Accepted: 24 November 2016
Published: 12 December 2016
Citation: 
Saxena A and Wu D (2016) 
Advances in Therapeutic Fc 
Engineering – Modulation of 
IgG-Associated Effector 
Functions and Serum Half-life. 
Front. Immunol. 7:580. 
doi: 10.3389/fimmu.2016.00580
Advances in Therapeutic Fc 
engineering – Modulation of  
igG-Associated effector Functions 
and Serum Half-life
Abhishek Saxena and Donghui Wu*
Laboratory of Antibody Engineering, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 
Shanghai, China
Today, monoclonal immunoglobulin gamma (IgG) antibodies have become a major option 
in cancer therapy especially for the patients with advanced or metastatic cancers. Efficacy 
of monoclonal antibodies (mAbs) is achieved through both its antigen-binding fragment 
(Fab) and crystallizable fragment (Fc). Fab can specifically recognize tumor-associated 
antigen (TAA) and thus modulate TAA-linked downstream signaling pathways that may 
lead to the inhibition of tumor growth, induction of tumor apoptosis, and differentiation. 
The Fc region can further improve mAbs’ efficacy by mediating effector functions such 
as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and 
antibody-dependent cell-mediated phagocytosis. Moreover, Fc is the region interacting 
with the neonatal Fc receptor in a pH-dependent manner that can slow down IgG’s 
degradation and extend its serum half-life. Loss of the antibody Fc region dramatically 
shortens its serum half-life and weakens its anticancer effects. Given the essential roles 
that the Fc region plays in the modulation of the efficacy of mAb in cancer treatment, 
Fc engineering has been extensively studied in the past years. This review focuses on 
the recent advances in therapeutic Fc engineering that modulates its related effector 
functions and serum half-life. We also discuss the progress made in aglycosylated mAb 
development that may substantially reduce the cost of manufacture but maintain similar 
efficacies as conventional glycosylated mAb. Finally, we highlight several Fc engineer-
ing-based mAbs under clinical trials.
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iNTRODUCTiON
Monoclonal antibodies (mAbs) can target tumors through specific recognition of tumor-associated 
antigens and subsequent recruitment of effector elements including macrophages, dendritic cells, 
natural killer (NK) cells, T-cells, and the complement pathway components (1). Such recruitments 
are achieved by interactions among the immunoglobulin gamma (IgG)-crystallizable fragment (Fc) 
and the immune cell receptors like Fcγ receptors (FcγRs) and the complement protein C1q of the 
complement system (2–4). These interactions lead to the activation of immune cells for enhanced 
antibody-dependent cellular cytotoxicity (ADCC)/antibody-dependent cell-mediated phagocyto-
sis (ADCP), formation of the membrane attack complex, and more efficient presentation of antigen 
FiGURe 1 | Schematics of immunoglobulin gamma overall structure and its binding regions with FcγRs, C1q, and FcRn. The constituent heavy [VH, 
CH1, hinge, CH2, and CH3 (gray)] and light chains [VL and CL (gray)] linked by inter-chain disulfide bonds are shown. The site at which FcγRs/C1q interacts with 
the crystallizable fragment (Fc) region is located in the lower hinge-upper CH2 (green rectangle); the site at which FcRn interacts with the Fc region is located in the 
interface of CH2–CH3 (yellow rectangle).
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to the dendritic cells (1). Through a recycling mechanism, the 
neonatal Fc receptor (FcRn) prolongs the half-life of mAbs in a 
pH-dependent interaction with the Fc region (5). The schematic 
of overall IgG structure and its binding regions with FcγRs, C1q, 
and FcRn is depicted in Figure 1.
The FcγRs, consisting of FcγRI (CD64), FcγRII (CD32), and 
FcγRIII (CD16) classes, are heterogeneous in terms of their cel-
lular expression and Fc binding affinities (1, 6). FcγRI binds to the 
Fc region with KD ~10−8–10−9 M and is expressed on mononuclear 
phagocytes, dendritic cells, and IFN-γ-activated neutrophils (1, 
7, 8). FcγRII binds to the Fc region with relatively lower affinity 
(KD ~10−7 M) and exists in five isoforms; among them, activating 
(FcγRIIa, harboring an immunoreceptor tyrosine-based activa-
tion motif on neutrophils) or inhibitory (FcγRIIb, harboring an 
immunoreceptor tyrosine-based inhibitory motif predominantly 
on B-lymphocytes) are critical for immune regulation (1, 7). 
FcγRIII, expressed in two isoforms, binds the Fc region with 
the lowest affinities (KD ~10−5 M) (1, 7). Among these, FcγRIIIa 
has a moderate Fc binding allele (V158) and a low binding allele 
(F158), and is expressed on NK cells, macrophages, and T-cell 
subsets and activates NK and T cell-mediated ADCC response 
(1, 6, 7); FcγRIIIb is exclusively present on neutrophils and lacks 
signal generation capacity (1, 7).
Crystal structures of Fc in complex with FcγRI (9) (Figure 2A), 
Fc in complex with FcγRII (10) (Figure 2B), and Fc in complex 
with FcγRIII (11) (Figure 2C) reveal that the FcγRs’ interaction 
sites on Fc are all located within the lower hinge-upper heavy 
chain constant domain 2 (CH2). Furthermore, the binding affin-
ity of Fc region to FcγRs also varies with the IgG subclasses (12).
The C1q is a multisubunit protein of the complement system 
(3). It uses one of its six heads to establish a low-affinity (~10−6 M) 
interaction with the lower hinge-upper CH2 domain of the Fc 
region (3). Crystal structure of the human C1q head revealed that 
it is assembled with a heterotrimer globular architecture (14). 
Though the molecular basis of how the C1q head recognizes the 
Fc region is not known at the atomic resolution, Schneider and 
Zacharias (15) proposed a working model of C1q in complex with 
Fc based on known experimental data, docking, and molecular 
dynamics simulation. According to this model, upon initial weak 
interaction between the C1q head and the Fc region, IgGs can 
aggregate while recognizing “multiple epitopes” on the antigen 
surface and thus give many C1q molecules an opportunity to 
bind to their Fc regions, which enhance the “cumulative affinity” 
to ~10−9 M (3, 15). This leads to the deposition of complement 
component 3 (C3b) on the target cell and ultimate formation of 
the membrane attack complex that disrupts the lipid bilayer of 
the target cell, promotes cytolysis, and completes complement 
dependent cytotoxicity (CDC) (16, 17).
The pharmacokinetic profiles of antibodies vary among sub-
classes and are related to the structural features of the Fc region 
(18, 19). It is known that the serum half-life of IgG subclasses 
(IgG1, IgG2, and IgG4) is ~23 days as compared to 2–6 days 
for IgG3 and other Ig classes (18, 19). The Fc region spanning 
the interface of CH2 and CH3 domains interacts with the FcRn 
in the placenta, liver, mammary glands, and adult intestine 
to regulate IgG homeostasis and deliver maternal IgG across 
the placenta to the fetus (5). This interaction is favored by an 
acidic environment of the endosome after IgG is pinocytosed 
FiGURe 2 | Crystal structures illustrating crystallizable fragment (Fc) interactions with FcγRs and FcRn. Representative structures are shown for (A) 
Fc–FcγRI cocrystals [PDB: 4W4O (9)], (B) Fc–FcγRII cocrystals [PDB: 3RY6 (10)], (C) Fc–FcγRIII cocrystals [PDB: 1T89 (11)], and (D) Fc–FcRn cocrystals [PDB: 
1I1A (13)] with β2 microglobulin (β2M) domain shown in cyan. The Fc region and FcγRs are represented by gray and yellow color, respectively (A–D). N297 glycans 
within the CH2 domain are shown in stick model. The critical binding regions are highlighted in the upper part of each panel; region from the Fc fragment in green, 
region from the FcγRs, FcRn, and β2M in red. The lower part of each panel shows the detailed residues, which are involved in the interactions between Fc and its 
binding partners.
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TABLe 1 | Tabulation of the Fc mutations known to mediate a profound effect on antibody effector functions and immunoglobulin gamma homeostasis.
Fc type Mutation Target Functional Reference
Hu-IgG2-Glyco K326W/E333S C1q Yes (52)
Mu-IgG2b-Glyco E235L FcγRI Yes (2)
Hu-IgG3-Glyco E235Y FcγRI Yes (35)
Hu-IgG1-Glyco S239D, I332E, S239D/I332E, and S239D/I332E/A330L FcγRIIIa Yes (6, 53–55)
Hu-IgG1-Glyco G236A, G236A/I332E, S239D/I332E, and G236A/S239D/I332E FcγRIIa > FcγRIIIa > FcγRI Yes (56)
Hu-IgG1-Glyco L235V/F243L/R292P/Y300L/P396L FcγRIIa Yes (57, 58)
Hu-IgG1-Glyco P238D/L328E FcγRIIb NA (59)
Hu-IgG1/IgA-Glyco IgGA (many motifs) FcγRs + FcαRI Yes (60)
Hu-IgG1-Glyco F243L/R292P/Y300L and F243L/R292P/Y300L/P396L FcγRIIIa/FcγRIIa Yes (29)
Hu-IgG1-Aglyco S298G/T299A FcγRIIa NA (61)
Hu-IgG1-(-Fuc) F234L FcγRIIIa Yes (62)
Hu-IgG1-Aglyco E382V/M428I FcγRI Yes (63)
Hu-IgG1-Aglyco Q295R/L328W/A330V/P331V/I332Y FcγRI Yes (64)
Hu-IgG1-Glyco M428L/N434S FcRn Yes (65)
Hu-IgG1-Glyco M252Y/S254T/T256E and H433K/N434F/Y436H FcRn Yes (66, 67)
Hu-IgG1-Glyco N343A/E380A FcRn Yes (68)
Hu-IgG1-Glyco M252Y/S254T/T256E FcRn Yes (69)
Hu-IgG1-Glyco T250R/M428L FcRn Yes (70)
Hu-IgG1-Aglyco Q295R/L328W/A330V/P331V/I332Y FcRn Yes (64)
Hu, Human; Mu, Murine; Glyco, Glycosylated; Aglyco, Aglycosylated; Fuc, Fucose; NA, not available.
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and thus IgG is protected from lysosomal degradation (20). 
The endocytosed IgG is then recycled to the cell surface and 
released into the blood stream at an alkaline pH, thereby main-
taining the sufficient IgG serum half-life for proper immune 
functions and desired therapeutic efficacies (20). Recently, the 
endothelial and hematopoietic cells are identified as the major 
sites associated with FcRn expression and their critical role in 
IgG homeostasis (20–23).
Based on site-directed mutagenesis of Fc region and design of 
a hybrid Fc heterodimer harboring one half of Fc wild type (WT) 
and one half of Fc mutant, Kim and coworkers identified the 
key Fc residues involved in the FcRn interaction and proposed a 
preliminary model that one Fc hinge homodimer bound with two 
FcRn molecules (24, 25). Shortly thereafter, Burmeister and cow-
orkers reported high resolution crystal structure of FcRn alone 
at 2.2  Å and low resolution crystal structure of Fc in complex 
with FcRn at 6.5 Å (26, 27). Structural analysis and biophysical 
data confirmed that one Fc homodimer binds with two FcRn 
molecules (26–29). Later, Martin and coworkers reported a high 
resolution crystal structure of Fc in complex with FcRn at 2.8 Å 
(13). This structure clearly shows the key residues involved in Fc 
and FcRn interactions and reveals the pH-dependent binding 
mechanism (13) (Figure 2D).
Evidence demonstrates the presence of oligosaccharides, 
attached to the N297 residue within the CH2 domain Asn-X-Ser/
Thr glycosylation motif of Fc region, is essential in maintaining 
the Fc conformation and mediating its interactions with FcγRs 
(FcγRI, FcγRIIa, FcγRIIb, and FcγRIIIa) and C1q, but not FcRn 
(30–41). The glycan moiety is formed by two N-linked bianten-
nary oligosaccharide chains consisting of a core heptasaccharide 
[N-acetylglucosamine (GlcNAc) and mannose (Man)] but occur-
rence of other residues like terminal N-acetlyneuraminic acid, 
galactose (Gal), bisecting N-acetylglucosamine (GlcNAc), and 
fucose (Fuc) have also been reported (1, 42, 43). Additionally, 
5–17 and 2–7% of IgG structures could be monosialylated 
and disialylated, respectively (1, 44). This imparts a significant 
complexity and heterogeneity to therapeutic IgG molecules when 
expressed in mammalian cells, which can affect the therapeutic 
profile of IgG (30). On the other hand, the presence of bisected 
N-acetylglucosamine structures in rituximab, a purer glycoform 
with lesser heterogeneity, leads to an efficient engagement of 
FcγRIII and increases ADCC activity against CD20+ cells by 
up to 20-fold (30, 45). Similarly, non-fucosylated glycoform of 
Herceptin produced in engineered Chinese hamster ovary (CHO) 
cell line (LEC13) can enhance ADCC via FcγRIII engagement by 
up to 50-fold (30, 46).
However, mAb-associated glycan heterogeneity poses sev-
eral key challenges (30, 33, 45–51) including (1) difficulties in 
developing therapeutic mAbs with glycan composition similar 
to naturally occurring human IgG1, (2) difficulties in controlling 
glycan heterogeneity, (3) lengthier development time to construct 
cell lines producing glycan homogeneity, (4) lengthier IgG pro-
duction time and higher manufacturing cost in mammalian cells 
as compared to that in E. coli or yeast-based expression systems, 
(5) dominance of particular glycoforms that can affect effector 
functions of IgG molecules, and (6) difficulties in separating vari-
ous glycoforms generated from mammalian cells. Alternatively, 
development of aglycosylated mAbs with similar efficacy as gly-
cosylated counterpart but lower manufacturing cost has attracted 
great efforts in the past decade.
In this review, we focus on the recent progress in therapeutic 
Fc engineering-associated effector functions (ADCC, ADCP, 
and CDC) and pharmacokinetics. The mutations known to 
induce profound effects on Fc interaction with FcγRs, C1q, and 
FcRn are summarized (see Table  1). We also briefly describe 
the advances in aglycosylated mAb development. Finally, we 
highlight clinical trials of several mAbs developed from relevant 
Fc engineering.
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MODULATiON OF eFFeCTOR FUNCTiONS 
BY Fc eNGiNeeRiNG
To develop more effective antibodies with desired ADCC, ADCP, 
and CDC activities, various strategies including site-directed 
mutagenesis, alanine scanning, structure-based computational 
design, and directed evolution technologies are employed.
The Fc amino acid residues that confer improved binding 
to FcγRs/C1q and enhanced immune response were initially 
characterized by site-directed mutagenesis studies. The earliest 
described mutations were discovered by scanning residues to 
isolate non-binders while focusing on the conserved residues. 
Fc residues (E318, K320, and L322) in the mouse IgG2b-Fc 
region were identified as the C1q binding site (3). However, the 
relevance of E318 and K320 was challenged in human Fc–C1q 
interaction (71). Novel residues (D270, K322, P329, and P331) 
were proposed for normal C1q binding on human Fc (71). This 
finding underscores the interspecies differences in such molecu-
lar interactions that may show a different effect in preclinical 
models. Furthermore, an IgG1 isotype of rituximab carrying 
K326W/E333S mutations was shown to have fivefold more bind-
ing to C1q (52) and the same motif, when transferred to the IgG2 
isotype (poor complement activator) of rituximab, increased 
the cell lysis by fivefold (52). Next, a single mutation from E to 
L at position 235 of the mouse IgG2b-Fc region proposed it to 
be the “major determinant” for FcγRI binding (with ~100-fold 
increased affinity to human monocyte FcγRI) (2). Additionally, 
using a mouse–human chimeric antibody, amino acids at posi-
tion 234 and 237 were shown to mainly influence the interaction 
with FcγRII. Based on these observations, FcγRI and FcγRII were 
proposed to recognize an overlapping but non-identical site on 
the Fc region (35).
Alanine scanning mutagenesis of selected Fc residues resulted 
in many variants with altered binding to specific FcγRs, which 
was also reflected in their ability to promote ADCC. Activating 
FcγRIIIa mutations improved ADCC by 100% (68). Furthermore, 
mutants based on the activating or suppressing effect on FcγRs 
were categorized into different classes. Among these, IgG1 
mutations A327Q/P329A (interact with FcγRI), D265A/S267A/
H268A/D270A/K326A/S337A (interact with FcγRIIa), and 
T256A/K290A/S298A/E333A/K334A (interact with FcγRIIIa) 
promoted high-affinity interactions (68).
Computational optimization of the Fc region by creating 
a single (S239D or I332E), double (S239D/I332E), and triple 
mutations (S239D/I332E/A330L) improved the affinity against 
human FcγRIIIaV158/F158 allele by up to 169-fold (6). The muta-
tions favoring Fc binding to activating (FcγRIIIa) receptor over 
the inhibitory (FcγRIIb) receptor are important to develop IgGs 
with better activating to inhibitory capacity (IIIa:IIb ratio), 
which was monitored using surface plasmon resonance. These 
mutations showed up to ninefold improvement in IIIa:IIb ratio 
and contributed to more than twofold enhancement in ADCC/
ADCP activity, and the S239D/I332E double mutant significantly 
depleted CD20+ B cells in  vivo compared to WT IgG (6). The 
same Fc mutations also enhanced in vitro ADCC/ADCP activ-
ity against lymphoma cell lines and directly translated into a 
more effective treatment of lymphoproliferative diseases when 
incorporated into anti-CD19/CD40 mAbs (53, 54). Furthermore, 
it was shown that a change from glycine to alanine at residue 236 
can shift the immune balance toward activating FcγRIIa relative 
to inhibitory FcγRIIb (56). The coupling of G236A to either I332E 
or S239D/I332E had dual beneficial effect as these mutants not 
only improve FcγRIIa:FcγRIIb ratio but also enhance binding to 
FcγRIIIa by ~6- to 31-fold (56). These mutants had significantly 
improved NK cell-mediated ADCC and macrophage-mediated 
ADCP activity (56).
In addition, “shuffled variants” of anti-CD20/CD57 antibody 
were constructed by grafting the CH1/hinge and CH3 carboxyl-
terminal of IgG1 into the Fc of IgG3 to retain both the ADCC 
activity from IgG1 and the CDC activity from IgG3 (72). It is 
known that IgG1 is the most potent ADCC activator, while 
IgG3 has highest potency to recruit complement system (72). 
Therefore, IgG1 and IgG3 Fc regions can complement one another 
to maximize the immune effector response. These variants with 
chimeric CH regions showed ~25–60% increase in ADCC and 
CDC activity compared to WT of IgG1 and IgG3 molecules (72). 
Furthermore, the CDC activity of humanized anti-CD20 IgG1 
(ocrelizumab) was increased by ~23-fold while retaining normal 
IgG1 ADCC by combining a triple mutant (S267E/H268F/S324T) 
with earlier reported G236A/I332E in the CH2 domain (73).
Multiple mutations (L235V/F243L/R292P/Y300L/P396L) in 
the trastuzumab Fc region (MGAH22) increased the potency 
against low Her2-expressing cells via low-affinity FcγRIIIaF158 
engagement (57). The same Fc motif was applied to the MGA271 
mAb (anti-CD276), which targets B7-H3+ tumor cells and 
resulted in an increased binding to FcγRIIIa, enhanced ADCC, 
and potent antitumor activity in a renal cell carcinoma/bladder 
cancer xenograft mouse model (58). Recently, the immune acti-
vating potential of IgA via FcαRI engagement was exploited by 
developing IgG and IgA hybrid molecules “IgGA” through sub-
stituting α1 loop residues of CHγ12/3 region with CHα12/3 (60). 
The “IgGA” hybrid trastuzumab mediated an enhanced ADCC/
ADCP activity against Her2 overexpressing cells and destroyed up 
to 50% SkBr3 breast cancer cells (via ADCC) and MDA-MB-453 
cells (via ADCP) (60). Similarly, “IgGA” hybrid rituximab lysed 
~70% of the CD20+ calcein-AM-loaded Raji tumor cells when 
compared to the WT counterparts (60).
A negative selection strategy was applied using yeast surface 
display to enrich Fc mutants exhibiting selective high affinity 
to FcγRIIIa (29). Among these isolates, F243L was predicted to 
make a direct contact with the carbohydrate portion, which can 
“influence sialylation and affect the quaternary structure” of the 
Fc domain (29). Additionally, R292P partially reduced the bind-
ing to FcγRIIa, while Y300L, in combination with other mutations 
(F243L/R292P/V305I/P396L), showed an ~10-fold less KD, 100-
fold enhanced ADCC activity, and potency in a xenograft mouse 
model of ovarian and breast cancer (29). Furthermore, an Fc vari-
ant with three changes (F243L/R292P/Y300L) was also effective 
in increasing the rate of cytolysis by ~100-fold (29). In another 
report, human IgG1 Fc variants were generated by an error-prone 
PCR and ribosome display to select high-affinity aglycosylated 
binders to human FcγRIIIa using a solution phase method (62). 
The isolated Fc mutant (F243L) lacked Fuc residues in most 
oligosaccharide chains and exhibited an improved FcγRIIIaV158/
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F158 binding and enhanced ADCC as compared to WT Fc (62). 
Recently, an anti-EGFR antibody (S239D/I332E) was noted to 
elicit mononuclear cell-mediated ADCC via FcγRIIIa engage-
ment and at the same time showed impaired polymorphonuclear 
cell (PMN)-mediated ADCC due to the engagement of FcγRIIIb, 
a highly homologous isoform to FcγRIIIa (55). The inability of 
FcγRIIIb to activate immune signaling in such a scenario can be 
overcome by imparting high-affinity binding to FcγRIIa, which 
can enhance both NK cell- and PMN mediated ADCC (55). These 
observations highlight that Fc engineering toward related FcγRs 
needs to be tailored specifically to achieve desirable immune 
effects.
MODULATiON OF ANTiBODY 
PHARMACOKiNeTiCS BY Fc 
eNGiNeeRiNG
Along with the efforts to engineer Fc regions for enhanced effec-
tor functions, attempts have been made to improve antibody 
pharmacokinetics. Clearly, enhanced Fc–FcRn interaction at 
acidic pH can extend IgG’s serum half-life and positively regulate 
its homeostasis, which may benefit patients by greater therapeutic 
efficacy, less frequent dosing, and lower cost burden. Alanine 
scanning and display/directed evolution are commonly used 
techniques to identify favorable Fc mutants that can strengthen 
Fc–FcRn pH-dependent interactions.
A human Fc variant (N434A), isolated by alanine scanning of 
all solvent-exposed residues, showed fourfold increased binding 
to FcRn at pH 6.0 (68), which later, when studied in cynomolgus 
monkeys, showed a twofold extension of IgG serum half-life 
confirming the modulation of pharmacokinetics (74). Such an 
interaction at pH 6.0 prolongs IgG availability in serum, which 
correlates with the therapeutic effectiveness as demonstrated 
by the improved antitumor activity of IgG-Fc mutant (M428L/
N434S from the CH3 domain) in a human FcRn transgenic 
mouse model (65).
A phage displayed antibody library approach was employed 
with the aim of isolating high-affinity binders against FcRn at pH 
6.0. Random mutations were created at residues T252, T254, and 
T256, which are proximal to the IgG–FcRn interaction site, and 
binders were selected in a solution phase against FcRn at pH 6.0 
and eluted by PBS at pH 7.4 (66). The Fc mutants generated in this 
manner were able to bind both human and rat FcRn with high 
affinity at pH 6.0; however, these variants (M252Y/S254T/T256E 
from the CH2 domain and H433K/N434F/Y436H from the CH3 
domain) also showed tighter binding to mouse FcRn at pH 7.4 
that decreased the serum IgG concentration in a mouse model 
(67). Yeung and coworkers (74) reported a similar observation 
that an Fc mutant (N434W), though possessing an ~80-fold 
enhanced affinity to FcRn at both acidic and neutral pH, did not 
stabilize serum IgG due to the loss in pH selectivity. These results 
suggest that high-affinity binding to the receptor at neutral pH 
can compromise the “beneficiary effect” of increased affinity at 
pH 6.0. Later, a humanized anti-respiratory syncytial virus anti-
body (MEDI-524) with a triple mutant Fc (M252Y/S254T/T256E 
from the CH2 domain) was reported to have a 10-fold increase 
in a pH-dependent way toward FcRn and about 4-fold improve-
ment in serum half-life in cynomolgus monkey (69). Similarly, a 
high-affinity Fc variant (T250R/M428L) bound FcRn selectively 
at pH 6.0 and accounted for a 2.8-fold lesser degradation of serum 
IgG2 (70) and IgG1 (75) in rhesus monkey. Accumulating stud-
ies highlight that to prolong IgG serum half-life, pH-dependent 
FcRn affinity has to be maintained.
Of note, Grevys and coworkers recently analyzed known 
IgG-Fc mutants, which show enhanced FcRn pH-dependent 
affinity and extended serum half-life (M252Y/S254T/T256E from 
the CH2 domain and M428L/N434S from the CH3 domain), for 
their effects on ADCC, ADCP, and CDC (65, 69, 76). Surprisingly, 
they found that both mutants showed reduced effector functions 
with regards to ADCC, ADCP, and CDC. More interestingly, 
they found one previously known mutant (H433K/N434F from 
the CH3 domain), which showed reduced FcRn pH-dependent 
affinity and shortened serum half-life, displayed enhanced effec-
tor functions in ADCP, CDC, and ADCC (76, 77). These findings 
highlight that, though the interaction region of Fc with FcγRs and 
C1q (lower hinge region-CH2 domain) is distant from its interac-
tion with FcRn (CH2–CH3 domain interface), it is still possible 
that these mutants can trigger a long range effect to other part of 
the Fc region in an unknown mechanism.
AGLYCOSYLATeD Fc TO OveRCOMe 
GLYCAN HeTeROGeNeiTY
The demand for therapeutic antibodies is high, and it has been 
estimated that 8,000  kg of clinical grade mAbs were produced 
in 2013 (78). Currently, ~50% of the clinical grade biologics are 
produced in mammalian cells like CHO, mouse myeloma cell 
lines NSO and SP2/0 (30, 78–80).
However, the inherent glycan heterogeneity of mAbs when 
expressed in mammalian cell systems can cause high production 
cost and variations of mAb functions from batch to batch. Recently, 
great efforts have been invested in developing aglycosylated mAbs 
as an alternative. Ideally, aglycosylated mAbs would be as efficient 
as or even better than its glycosylated peers in mediating effector 
functions for antigen or target cell clearance.
To develop aglycosylated IgGs as alternatives, Sazinsky 
and coworkers constructed three small subsets of saturation 
substitutions covering the Asn-X-Ser/Thr glycan motif of the Fc 
C′/E loop and displayed these libraries on the yeast cell surface 
(61). After selection against FcγRIIa by fluorescence-activated 
cell sorting (FACS), a double Fc mutant isolate (S298G/T299A) 
in an aglycosylated form showed threefold stronger binding as 
compared to the WT and variants with single mutation, which 
indicates that the glycosylation of N297 is not a strict require-
ment for the interaction of Fc with FcγRIIa (61). In contrast, 
the indispensable role of asparagine at position 297 was demon-
strated in the backdrop of N297Q, N297D, or N297A mutation, 
which abolished the double mutant (S298G/T299A) binding to 
FcγRIIa (61). Moreover, this dual mutant is functional in vivo 
in that murine platelet clearance is as efficient as that of WT 
mAb. Based on the modeling of Fc dual mutants in complex 
with FcγRIIa, the N297 residue of an aglycosylated IgG can 
TABLe 2 | Fc-engineered antibody candidates under clinical evaluation.
Antibody Target Fc modification Disease Clinical development Company Reference
BI836826 CD37 NA CLL Phase-1 Boehringer (6, 88, 89)
JNJ56022473 CD123 NA AML Phase-2 Janssen R & D (89–91)
XmAb2513 CD30 NA Hodgkin/large cell lymphoma Phase-1 Xencor, Inc. (89, 92, 93)
XmAb5871 CD19 S267E/L328F SLE Phase-1 Xencor, Inc. (90, 94)
XmAb7195 IgE S267E/L328F Allergic diseases Phase-1 Xencor, Inc. (95)
XmAb5774 CD19 S239D/I332E CLL Phase-1 Xencor, Inc. (89, 96)
TRX4 CD3 N297A Type-1 diabetes mellitus (autoimmune) Phase-3 GSK/Tolerx (48, 49, 97)
Onartuzumab MET N297A NSCLC/gastroesophageal cancer Phase-3 Roche (48, 98, 99)
ALD518 IL-6 N297A RA/NSCLC/oral mucositis Phase-2 Alder (48, 49, 100)
TRX518 GITR N297A Malignant melanoma Phase-1 Tolerx (48, 49, 101)
CLL, chronic lymphocytic leukemia; AML, acute myeloid leukemia; SLE, systemic lupus erythematosus; NSCLC, non-small cell lung cancer; RA, rheumatoid arthritis; 
NA, not available.
Source: https://clinicaltrials.gov/.
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make a hydrogen bond with the S126 residue of FcγRIIa (61, 
81). Furthermore, such interaction may be strengthened by a 
bridging water molecule present in an unbound FcγRII crystal 
(61, 81). However, this dual mutant showed 10-fold reduced 
FcγRI binding and no binding to both FcγRIII and C1q proteins. 
The inability of aglycosylated mAbs to bind with C1q and thus 
activate CDC can limit their application in treating hospital 
acquired microbial infections among cancer patients where 
complement activity plays an important role (82).
In another major breakthrough, bacterial display and FACS 
was used to isolate Fc variants displaying increased binding and 
specificity to FcγRI (63). One such aglycosylated variant called 
“Fc5” (E382V/M428I) was incorporated into trastuzumab. The 
trastuzumab-Fc5 variant bound selectively to the FcγRI with 
nanomolar range affinity and promoted monocyte-derived den-
dritic cell-dependent lysis of SkBr3 breast cancer cells that over-
express Her2. (63). The three-dimensional structure of human 
aglycosylated Fc domain suggests a greater “conformational 
flexibility of the CH2-CH3 domain interface,” as compared to the 
glycosylated counterpart (83). Additional mutations (Q295R/
L328W/A330V/P331V/I332Y) in trastuzumab-Fc5 variant 
(63) increased the affinity for FcγRI by ~120-fold and retained 
pH-dependent FcRn binding and function (64). Other mutants 
were also reported with specific binding to FcγRI and without 
compromising the pH-dependent FcRn binding (84).
It is worth mentioning that removal of appended glycans, 
though does not affect IgG’s solubility, binding affinities to FcγRs, 
and in  vivo half-life but often compromises IgG related CDC, 
lowers its thermostability and increases its aggregation at the low 
pH (85–87).
Fc eNGiNeeRiNG-BASeD mAbs UNDeR 
CLiNiCAL TRiALS
A number of mAbs harboring various modifications in the Fc 
region are being investigated in different clinical trial stages 
(see Table  2 for Fc engineering-based mAbs being tested in 
clinics). These molecules broadly fall into three categories (1) 
with enhanced effector response to treat cancer and infectious 
diseases, (2) capable of inhibiting immune activation to treat 
inflammatory diseases, and (3) new class of aglycosylated mAbs 
with either inert or active-immune function.
The Fc variants capable of inducing enhanced ADCC are 
being tested in many antibody candidates. Anti-CD37 antibody 
(BI836826; Boehringer) against B cell malignancies is currently 
under phase-1 trial for the treatment of chronic lymphocytic 
leukemia (CLL) (6, 88, 89). This is a mouse–human chimeric 
antibody, which targets tetraspanin CD37 and shows high proa-
poptotic activity against malignant B cells via enhanced ADCC. 
Using human CD37 transgenic mice, a single dose of BI836826 
was demonstrated to reduce peripheral B cells (88) and effica-
cious in suppressing tumor growth in Ramos mouse model of 
human B-cell lymphoma (88). Furthermore, therapeutic efficacy 
of a surrogate Fc-engineered antibody against macaque CD37 
has also been demonstrated in cynomolgus monkey (88). A fully 
humanized anti-CD123 antibody (JNJ-56022473; Janssen R & D) 
targeting overexpressed interleukin-3 receptor α-chain is being 
tested in acute myeloid leukemia patients (89–91). The Fc frag-
ment of JNJ-56022473 has been engineered for enhanced NK cell-
mediated ADCC. The molecule efficiently reduced the growth of 
the patient-derived acute myelogenous leukemia xenografts in 
bone marrow and peripheral organs and increased the survival in 
animal models (91). Similarly, a humanized anti-CD30 antibody 
(XmAb2513; Xencor) with enhanced binding to FcγRIIIa is being 
evaluated in the treatment of CD30+ Hodgkin’s lymphoma (HL) 
patients who had previously received two or more therapies (89, 92, 
93). It has been shown to be safely administered and biologically 
active in relapsed, refractory HL subjects and reduces tumor in a 
majority of patients (92, 93). Another interesting molecule is an 
anti-CD19 antibody (XmAb5774; Xencor), which induces potent 
NK cell-mediated ADCC/ADCP response against CLL (89, 96). 
The antibody is known to get internalized in primary CLL cells 
and induces a modest toxicity (96).
Antibodies harboring Fc mutations that can suppress the 
immune response are being tested for the treatment of inflam-
matory diseases. The immunosuppressive version of anti-CD19 
antibody (XmAb5871; Xencor) binds inhibitory FcγRIIb with 
~430-fold enhanced affinity and efficiently depletes CD19+ B-cells 
in systemic lupus erythematosus (SLE) patients (90, 94). The 
depletion of CD19+ B-cells correlates with the strong inhibition 
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of B-cell receptor-induced calcium mobilization among healthy 
volunteers and SLE patients (94). The same Fc fragment has been 
engineered into a humanized anti-IgE antibody (XmAb7195; 
Xencor) for the treatment of allergies (95). This antibody prevents 
the binding of IgE to its high-affinity IgE receptor (FcϵRI) that is 
present on basophils and mast cells and is useful in the treatment 
of allergic asthma (95). The XmAb7195 has 5- and ~430-fold 
higher affinity for human IgE and FcγRIIb, respectively, and 
therefore is effective in inhibiting IgE production and plasma cell 
differentiation (95).
Finally, aglycosylated IgG molecules have recently been shown 
to have therapeutic properties (48, 49, 61, 63), and a few of them 
are undergoing clinical testing. An anti-CD3 antibody (TRX4; 
Tolerx) incorporating the N297A mutation suppresses pathogenic 
T-cells in type-1 diabetes (T1D) patients (48, 49, 97) and is being 
evaluated in phase-3 trials. The antibody downregulates patho-
genic T-cells while restoring the normal activity of T-regulatory 
cells and thereby inhibits autoimmune mediated T1D (97).
It is widely accepted that hepatocyte growth factor (HGF) 
binding to receptor tyrosine kinase MET aggravates malignancy 
in a variety of cancers (98). Therefore, an aglycosylated anti-
MET antibody (Onartuzumab; Roche) is being evaluated in 
phase-3 trials to inhibit the binding of HGF for treating lung and 
gastroesophageal cancers (49, 98, 99). This is an E. coli-derived 
humanized, affinity-matured antibody, which engages MET, 
thereby inhibiting HGF binding and receptor phosphorylation in 
HGF-dependent tumor models (98). Similarly, an aglycosylated 
mAb (ALD518; Alder) targeting IL-6 is being tested in phase-2 
for a variety of diseases including rheumatoid arthritis, non-small 
cell lung cancer (NSCLC), and oral mucositis (48, 49, 100). The 
antibody was developed to inhibit proinflammatory cytokine 
IL-6 in oncogenic niches, which can otherwise lead to a cancer. 
The mAb ALD518 is reported to be well tolerated in phase-1 and 
-2 studies and ameliorated NSCLC-related anemia and cachexia 
(100). Another aglycosylated mAb (TRX518; Tolerx) is currently 
in phase-1 trials to treat malignant myeloma (48, 49, 101). TRX518 
mAb recognizes the glucocorticoid-induced tumor necrosis fac-
tor receptor on regulatory and effector T-cells, B-cells, NK cells, 
and antigen-presenting cells to enhance effector T-cell response 
and inhibits T-regulatory cell-mediated suppression (101). 
Furthermore, the efficacy of TRX518 mAb in reducing tumor 
burden and increased survival rates has been demonstrated in 
mouse and non-human primate models (101).
These studies highlight that Fc engineering has played impor-
tant roles in developing antibodies with desirable properties and 
functions, and the ongoing clinical studies can give valuable 
information on the efficacy of the Fc-engineered mAbs, as com-
pared to their existing peers.
FiNAL ReMARKS
Crystallizable fragment engineering has made substantial pro-
gress in the identification of new mutant(s) that can enhance 
effector functions and improve pharmacokinetics of mAbs for 
cancer treatment. Two major notions have emerged during the 
past decades’ efforts. First, the ratio of human activating FcγRs 
(FcγRI, FcγRIIa, and FcγRIIIa) and inhibitory FcγR (FcγRIIb) has 
to be taken into account during Fc engineering design. Beneficial 
effect can be achieved when Fc mutant(s) show higher selectivity 
and binding affinity toward activating FcγRs, as compared to 
the inhibitory FcγR. Second, the synergistic effects of improved 
ADCC, ADCP, and CDC of Fc region could increase the potency 
in cancer treatment.
Excitingly, aglycosylated mAb, expressed in bacteria and yeast, 
have been found to possess similar properties as glycosylated 
mAb with regards to FcγRs binding and serum half-life. However, 
efforts are still needed to improve its thermostability, solubility, 
and its binding affinity to C1q and CDC activity before it can 
really compete with its glycosylated peer for cancer therapy. On 
the other hand, the inability of aglycosylated mAbs to bind to C1q 
may have beneficial effects when CDC activity is not required such 
as for treatment of autoimmune diseases where CDC is chroni-
cally and pathologically activated (102). Similarly, aglycosylated 
mAbs may have advantages over glycosylated counterparts when 
only selective activation of FcγRs is desired such as activation of 
FcγRI (63) or FcγRIIa (84) to stimulate tumor cell killing.
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